NEAR Protocol sets 2026 priorities around AI-Intents convergence, user-owned AI, and expanding NEAR Intents into a top trading platform. The protocol hit 1 millionNEAR Protocol sets 2026 priorities around AI-Intents convergence, user-owned AI, and expanding NEAR Intents into a top trading platform. The protocol hit 1 million

NEAR Protocol Outlines 2026 Roadmap Focused on Intents, AI, and the Next Growth Cycle

  • NEAR Protocol sets 2026 priorities around AI-Intents convergence, user-owned AI, and expanding NEAR Intents into a top trading platform.
  • The protocol hit 1 million TPS, added three shards, and launched AI Cloud tools already serving over 100M users across multiple platforms.

NEAR Protocol has published its roadmap for 2026, signaling a shift toward artificial intelligence, decentralized trading, and broader protocol adoption. The Layer 1 blockchain aims to grow NEAR Intents into a leading venue for on-chain transactions, expand its AI efforts, and position $NEAR as a core digital asset in the evolving crypto economy.

The announcement followed a high-performance year in 2025, which NEAR described as its transition to real-world scale. The protocol reached a major technical benchmark, hitting one million transactions per second (TPS) in a public test using live core code and accessible hardware. 

According to NEAR, this proves the viability of sharded blockchain architecture in supporting high-load decentralized applications.

In 2025, NEAR scaled its mainnet infrastructure from six to nine shards, raising throughput by 50%. With dynamic resharding now active, the network can adjust its structure as demand increases. This offers a route to horizontal scalability without disrupting application performance.

“Sharding lets us scale execution across Intents,” NEAR posted, emphasizing the ability to handle higher transaction volumes. The network’s flexibility is crucial to its broader plans to serve as the base layer for AI and intent-based transactions.

As CNF outlined, NEAR’s infrastructure upgrades come as rival networks like Polygon continue to evolve their zkEVM architecture and cross-chain tooling.

NEAR’s AI Cloud and Privacy-Preserving Tools Go Live

The NEAR Foundation introduced two key products, as reported by CNF: NEAR AI Cloud and Private Chat, which enhance AI interaction while protecting user data. These tools are designed around the principle of verifiable privacy, meaning user inputs and outputs are cryptographically protected and owned by the user.

Both tools are already integrated into Brave Nightly, OpenMind AGI, and Phala Network applications, reaching over 100 million users. They run on hardware-backed encryption, offering an alternative to centralized AI systems.

As NEAR stated, “Users should own their interactions with AI.” The move positions NEAR to support both the privacy and usability demands of decentralized AI products.

Alongside technical progress, NEAR is exploring a new governance model called the “House of Stake.” This system will blend community participation with support from intelligent digital agents capable of representing user intent. The protocol claims this structure moves beyond binary voting by enabling more context-aware decision-making.

The 2026 roadmap release and a gradual market upturn in recent days have boosted the NEAR price. In the last 24 hours, the NEAR price was trading over 8% higher from its intraday low at $1.63

]]>
Market Opportunity
NEAR Logo
NEAR Price(NEAR)
$1.52
$1.52$1.52
+0.52%
USD
NEAR (NEAR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26